Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Oncology"
DOI: 10.3892/ijo.2018.4364
Abstract: CD44v6 is overexpressed in a variety of cancers, rendering it a promising target for radio-immunotherapy (RIT). In this study, we have characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody, AbN44v6, and assessed its potential for… read more here.
Keywords: radio immunotherapy; cd44v6; antibody; abn44v6 ... See more keywords